NCT07219407View on ClinicalTrials.gov

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 3, 2025

Primary Completion Date

February 3, 2028

Study Completion Date

February 3, 2028

Conditions
Focal EpilepsyEpilepsyRefractory Focal EpilepsySeizureFocal SeizureFocal Onset Seizure
Interventions
DRUG

RAP-219

Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.

All Listed Sponsors
lead

Rapport Therapeutics Inc.

INDUSTRY

NCT07219407 - A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures | Biotech Hunter | Biotech Hunter